[ad_1]
The European Commission has not yet concluded pre-purchase agreements with these companies, but has completed exploratory talks.
Under the planned agreement with Novavax, all EU Member States could acquire 100 million euros. doses and could buy up to an additional 100 million. dose.
At that time, under the agreement envisaged with Valneva, all members of the Community could acquire 30 million euros. dose and could claim up to an additional 30 million. dose.
Once negotiations with Novavax and Valneva are complete, Europe will have contracts with eight different manufacturers for more than 2.5 billion euros. dose of vaccine.
The EU has already signed contracts with AstraZeneca, Johnson & Johnson, Sanofi and GSK, Pfizer and BioNTech, CureVac, Moderna.
So far, the European Medicines Agency (EMA) has approved three vaccines: Pfizer and BioNTech, and Moderna and AstraZeneca.
According to information published by the Ministry of Health in mid-January, according to existing agreements with manufacturers, Lithuania would need more than 9 million. dose of vaccine.
[ad_2]
